Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer surgeries in the United States, in 30% of procedures in Asia, and in as few as 10% to 20% of procedures in Europe.
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, discusses cardiac toxicities in cancer survivors, a new topic for the NCCN Survivorship Guidelines this year, and the need for more research on this important side effect, including prevention and surveillance.
Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, the “financial toxicities” of high drug prices, and what could and should be done about it.
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and David S. Ettinger, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss the evolution of the NCCN Guidelines, the importance of including palliative care and survivorship recommendations, and the use of the guidelines in community practices.
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource availability. The first guideline to be adapted in this way is for cervical cancer, which is prevalent in the developing world.
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
